• Merck announces a non-binding MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies
• Integrates company’s BioContinuum™ Platform in Mycenax’s Contract Development and Manufacturing Services (CDMO) for maximum safety, control, transparency, and repeatability
• Collaboration aims to enhance process intensification, advance towards BioProcessing 4.0 and continuous bioprocessing

"Digital transformation in biomanufacturing is creating a paradigm shift towards a bioprocessing facility-of-the-future that is data-intensified, connected and seamless in continuous processing,” said Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck. “By combining the strengths of Merck and Mycenax in Contract Development and Manufacturing Services, we aim to accelerate the development of new products and process innovations. This will enhance resilience in both research and production.”

As part of the MoU, Merck will explore with Mycenax the provision of its extensive support including consultation, technical assistance, and training, ensuring Mycenax receives expert guidance for optimal performance. Recognizing the importance of economic viability, the collaboration will also seek ways to incorporate in-depth cost modelling for better process economics. This strategic analysis aims to enhance cost-effectiveness in next generation bioprocessing.

"Mycenax consistently seeks better solutions and areas for optimization. The integration of continuous processing and Industry 4.0 is not only a future mainstream trend but also possesses the potential for continuous growth," said Pei-Jiun Chen, Ph.D., Chairman/CEO and President of Mycenax. "The collaboration with Merck aims to provide innovative continuous processing solutions in the market, to boost our international standing and cater to diverse biopharmaceutical needs."